ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer.

Qin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.